ANI Pharmaceuticals Q1 2024: record revenue $137.4M, EPS $0.82; reiterates FY guidance

ANI PHARMACEUTICALS INC

2024-Q1 EPS reported $0.82 revenue$137,430,000

Q1 net revenue $137.4M (+28.7% YoY); GAAP diluted EPS $0.82 vs $0.06; adjusted non-GAAP EPS $1.21.
Rare Disease segment (Cortrophin Gel) revenue $36.9M, up 126.2% YoY on higher volume.
Generics, Established Brands and Other segment revenue $100.5M, up 11.1% YoY; launched six new generics.
FY2024 guidance reaffirmed: revenue $520M-$542M; adjusted EBITDA $135M-$145M; adjusted EPS $4.26-$4.67.
Ended quarter with $228.6M cash; sold Oakville facility for $14.2M, recognized $9.7M gain on CG Oncology IPO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ANI PHARMACEUTICALS INC reported the quarter ended March 31, 2024 results: revenue $137.4 million, net income $17.8 million, EPS $0.82. Guidance reaffirmed.

Period: the quarter ended March 31, 2024
Revenue: $137.4 million
Net income: $17.8 million
EPS: $0.82
Guidance: reaffirmed
Result: reported results

Exact text from the filing

ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance • Generated record quarterly net revenues of $137.4 million, representing year-over-year growth of 28.7%, net income to common shareholders of $17.8 million, and GAAP diluted earnings per share of $0.82

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

ANI PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001023024-24-000055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.